TBPH - テラバンス・バイオファ―マ (Theravance Biopharma Inc.)

TBPHのニュース

   Theravance Biopharma''s Ampreloxetine Shows Benefit In Atrophy Patients, But Not In Parkinson''s  2022/04/05 12:49:12 Benzinga
Theravance Biopharma Inc (NASDAQ: TBPH ) revealed results from the second Phase 3 study assessing ampreloxetine compared to placebo for symptomatic nOH. Neurogenic orthostatic hypotension (nOH) is a rare disorder defined as a sustained orthostatic fall in blood pressure within three minutes of standing. The primary endpoint was treatment failure at week 6 of the randomized withdrawal period. The primary endpoint was not statistically significant for the overall population of patients, … Full story available on Benzinga.com
   The Daily Biotech Pulse: Thervance Gains On Positive Late-Stage Readout, Bristol-Myers Squibb Snags 3 Approvals In Europe, Decision Day For BioXcel  2022/04/05 11:48:52 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Theravance Announces Phase 3 Data For Ampreloxetine Showing Clear Benefit In Multiple System Atrophy Patients Theravance Biopharma, Inc. (NASDAQ: TBPH ) announced results from the second Phase 3 study, assessing the durability of clinical effect of ampreloxetine compared to placebo for the treatment of symptomatic neurogenic orthostatic hypotension. The primary endpoint was not statistically significant for the overall population of patients, which included patients with Parkinson''s disease, pure autonomic failure and multiple system atrophy. Yet the pre-specified subgroup analysis by disease type suggests the benefit seen in patients receiving ampreloxetine was largely driven by MSA patients. The stock was advancing 5.26% to $10 in premarket trading. Novartis Receives Approval To Manufacture Zolgensma In Second Manufacturing Facility In US Novartis AG (NASDAQ: NVS ) said the U.S. Food and Drug Administration has granted commercial licensure approval for its Durham, North Carolina site, a multiproduct gene therapy manufacturing facility.
   Theravance Biopharma hypotension drug fails to meet primary goal  2022/04/04 21:24:08 Financial Post
Theravance Biopharma Inc said on Monday its experimental drug to treat a form of low-blood pressure failed to show significant improvement in the overall patient population of a late-stage study, but showed a benefit in patients with a rare neurological disorder. The drug, ampreloxetine, was being tested in patients with symptomatic neurogenic orthostatic hypotension (nOH), […]
   TBPH stock slips after setback for ampreloxetine in hypotension trial (NASDAQ:TBPH)  2022/04/04 20:27:33 Seeking Alpha
Commercial-stage pharma company, Theravance Biopharma (TBPH) has lost ~5% in the post-market Monday after announcing that its second Phase 3 trial for ampreloxetine in…
   Why Theravance Biopharma Stock Is Trading Lower After Hours  2022/04/04 20:25:03 Benzinga
Theravance Biopharma Inc (NASDAQ: TBPH ) shares are trading lower in … Full story available on Benzinga.com
   Theravance Biopharma to Report Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022 | MarketScreener  2022/02/09 11:01:28 MarketScreener
DUBLIN, Feb. 9, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. will report its fourth quarter and full year 2021 financial results and provide a business update after market close on Wednesday,… | February 9, 2022
   Theravance Biopharma Inc Shares Close the Week 23.8% Lower - Weekly Wrap  2022/01/17 21:27:26 Kwhen Finance
Theravance Biopharma Inc (TBPH) shares closed this week 23.8% lower than it did at the end of last week. The stock is currently down 10.6% year-to-date, down 45.1% over the past 12 months, and down 70.0% over the past five years. This week, the Dow Jones Industrial Average fell 0.9%, and the S&P 500 fell 0.3%. Trading Activity Shares traded as high as $13.17 and as low as $9.26 this week.Trading volume this week was 20.1% lower than the 10-day average and 20.9% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.4. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price lags the S&P 500 Index this week, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average this week, lags it on a 1-year basis, and lags it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 37.3% The company's stock price performance over the past 12 months lags the peer average by -1291.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Theravance Biopharma (TBPH) Investor Prsentation - Slideshow  2022/01/15 21:18:37 Seeking Alpha
   Theravance Biopharma Inc Shares Close the Day 11.1% Higher - Daily Wrap  2022/01/04 11:09:05 Kwhen Finance
Theravance Biopharma Inc (TBPH) shares closed today 11.1% higher than it did at the end of yesterday. The stock is currently up 11.1% year-to-date, down 30.9% over the past 12 months, and down 62.2% over the past five years. Today, the Dow Jones Industrial Average rose 0.6%, and the S&P 500 rose 0.6%. Trading Activity Shares traded as high as $13.13 and as low as $10.35 this week.Shares closed 46.0% below its 52-week high and 101.3% above its 52-week low.Trading volume this week was 59.6% lower than the 10-day average and 61.8% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.6. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 918.2% The company's stock price performance over the past 12 months lags the peer average by -223.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   The Theravance Biopharma Inc. (NASDAQ: TBPH) Stock Dropped 30.29% In A Single Month Are There Any Hopes For A Gain?  2021/12/16 14:00:00 Marketing Sentinel
During the last session, Theravance Biopharma Inc. (NASDAQ:TBPH)s traded shares were 1.53 million, with the beta value of the company hitting 0.77. At the end of the trading day, the stocks price was $10.71, reflecting an intraday gain of 4.69% or $0.48. The 52-week high for the TBPH share is $22.74, that puts it down The Theravance Biopharma Inc. (NASDAQ: TBPH) Stock Dropped 30.29% In A Single Month Are There Any Hopes For A Gain? Read More »
   Acute Lung Injury Market: Industry Analysis, Drugs, Key Companies by DelveInsight | Altor BioScience, Apeiron Biologics, Theravance Biopharma, Viela Bio, ReAlta Life Sciences, Cantex Pharmaceuticals  2021/05/18 01:22:01 AB Newswire
   Theravance Biopharma (NASDAQ:TBPH) Price Target Lowered to $39.00 at SVB Leerink  2021/05/12 11:42:46 Dakota Financial News
Theravance Biopharma (NASDAQ:TBPH) had its price objective lowered by SVB Leerink from $40.00 to $39.00 in a research report sent to investors on Tuesday morning, Benzinga reports. SVB Leerink currently has an outperform rating on the biopharmaceutical companys stock. SVB Leerink also issued estimates for Theravance Biopharmas Q2 2021 earnings at ($0.78) EPS, Q3 2021 []
   Head-To-Head Contrast: Spotlight Innovation (OTCMKTS:STLT) vs. Theravance Biopharma (NASDAQ:TBPH)  2021/05/12 01:06:44 Dakota Financial News
Spotlight Innovation (OTCMKTS:STLT) and Theravance Biopharma (NASDAQ:TBPH) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, valuation, dividends and profitability. Insider and Institutional Ownership 80.4% of Theravance Biopharma shares are owned by institutional investors. 5.9% []
   Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Average Rating of Buy from Analysts  2021/05/11 20:20:41 Transcript Daily
Theravance Biopharma, Inc. (NASDAQ:TBPH) has earned a consensus recommendation of Buy from the nine analysts that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation and eight have assigned a buy recommendation to the company. The average 12-month target price among brokers that have updated their coverage []
   Theravance Biopharma (NASDAQ:TBPH) Price Target Lowered to $32.00 at Needham & Company LLC  2021/05/11 14:06:41 Dakota Financial News
Theravance Biopharma (NASDAQ:TBPH) had its price objective reduced by investment analysts at Needham & Company LLC from $40.00 to $32.00 in a note issued to investors on Tuesday, Benzinga reports. The brokerage currently has a buy rating on the biopharmaceutical companys stock. Needham & Company LLCs price target would indicate a potential upside of 66.75% []

calendar